17371-99-2

Usage

Uses

Used in Chemical Synthesis:
2-Mercapto-5-phenylbenzoxazole is used as a reactant in the preparation of α-sulfenyl monoketones. These monoketones are valuable intermediates in the synthesis of various organic compounds, including pharmaceuticals, agrochemicals, and specialty chemicals. The presence of the thiol group in 2-Mercapto-5-phenylbenzoxazole allows for the formation of α-sulfenyl monoketones through reactions such as oxidation or coupling with other organic compounds.
Used in Pharmaceutical Industry:
2-Mercapto-5-phenylbenzoxazole can be used as a building block or a key intermediate in the synthesis of pharmaceutical compounds. Its unique structure and reactivity can be exploited to design and develop new drugs with potential therapeutic applications. The benzoxazole ring system is known to exhibit a wide range of biological activities, and the addition of the thiol group can further enhance or modulate these properties.
Used in Material Science:
2-Mercapto-5-phenylbenzoxazole can also find applications in the field of material science, particularly in the development of new materials with specific properties. For example, it can be used to synthesize novel polymers, coatings, or adhesives with improved performance characteristics. The thiol group can participate in various chemical reactions, such as cross-linking or grafting, to create materials with tailored properties.

InChI:InChI=1/C13H9NOS/c16-13-14-11-8-10(6-7-12(11)15-13)9-4-2-1-3-5-9/h1-8H,(H,14,16)

Upstream product

• 1134-36-7 2-amino-4-phenylphenol 
• 75-15-0 carbon disulfide 
• 140-89-6 potassium ethyl xanthogenate 

Downstream Products

• 439607-88-2 2-chloro-5-phenylbenzooxazole 
• 114997-08-9 3-[N-(5-Phenyl-benzooxazol-2-yl)-hydrazino]-propionitrile 
• 124783-15-9 2-(methylthio)-5-phenylbenzo[d]oxazole 

Relevant academic research and scientific papers

DIAZEPANE COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR

Compounds of formula (I) are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain.

NOVEL PIPERAZINES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF

Disclosed are novel piperazine derivatives that act as agonists of the α7 nAChR. Also disclosed are phannaceutical compositions, methods of treating inflammatory conditions, methods of treating CNS disorders, methods for inhibiting cytokine release from mammalian cells and methods for the preparation of the novel compounds.

COMPOUNDS, COMPOSITIONS AND METHODS OF INHIBITING A-SYNUCLEIN TOXICITY

Compounds and compositions are provided for treatment or amelioration of one or more symptoms of α-synuclein toxicity, α-synuclein mediated diseases or diseases in which α-synuclein fibrils are a symptom or cause of the disease. In one embodiment, the compounds for use in the compositions and methods are heteroaryl acylguanidines, heteroarylhydrazones, dihydropyridones, heteroaryl and aryl styryl ketones, and heteroarylpyrazoles.

Pharmaceutical composition for the treatment of CNS and other disorders

The present invention relates to a method of treating disorders of the Central Nervous System (CNS) and other disorders in a mammal, including a human, by administering to the mammal a CNS-penetrant α7 nicotinic receptor agonist. It also relates to pharma

Pharmaceutical compositions for CNS and other disorders

The present invention relates to a method of treating disorders of the Central Nervous System (CNS) and other disorders in a mammal, including a human, by administering to the mammal a CNS-penetrant α7 nicotinic receptor agonist. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier and a CNS-penetrant α7 nicotinic receptor agonist.

Benzoxazoline and benzimidazoline derivatives as novel aldose reductase inhibitors, part 2: Lead optimization

We designed novel aldose reductase inhibitors, benzoxazoline and benzimidazoline derivatives, based on lead evolution from spiroquinazolinones. In order to optimize in vivo activity in the lens, variously substituted derivatives were synthesized. The relationship between structure and in vitro activity was also analyzed by comparative molecular field analysis. The optimized compound exhibited high potency in the lens.

3-[1-(2-Benzoxazolyl)hydrazino]propanenitrile derivatives: Inhibitors of immune complex induced inflammation

3-[1-(2-Benzoxazolyl)hydrazino]propanenitrile derivatives were evaluated in the dermal and pleural reverse passive Arthus reactions in the rat. In the pleural test these compounds were effective in reducing exudate volume and accumulation of white blood cells. This pattern of activity was similar to that of hydrocortisone and different from that of indomethacin. The structural requirements for inhibiting the Arthus reactions were studied by systematic chemical modification of 1. These structure-activity relationship studies revealed that nitrogen 1' of the hydrazino group is essential for activity and must be electron rich, whereas chemical modifications of other sites of 1 had only a modest effect on activity.